ARCHIVES

AVEO’s Tivozanib Sunk by Fundamental Flaw: Higher Overall Survival in the Control Arm

This article is from The Cancer Letter archive.

Vol. 39 No. 18 | May 8, 2013

Download PDF Visit The Full Archive

Related Articles

NCIs FY95 Bypass To Justify $3.47 Billion, includes $490 million For Breast Cancer Research

May 14, 1993

Indiana to Close Proton Beam Facility Amid Nationwide Building Boom

October 17, 2014

Vitamin D Not Associated With Risk For Less Common Cancers, Study Finds

July 30, 2010

In Brief: Cancer Program Get Shot In Arm With Override Of Appropriations Vet; Carter To Leave NCI

February 6, 1976

ASCO Honors Eight With Special Awards

May 24, 2002

In Brief: Weicker Joins Tobacco Company Board; Hatfield To Leave Senate Next Year

December 8, 1995